Supreme Court Declines Review of Medicare Drug Price Negotiation Lawsuits
The U.S. Supreme Court declined to hear challenges to the Medicare drug price negotiation program. The Maryland Prescription Drug Affordability Board agreed to set an upper payment limit for Ozempic. The White House expanded its TrumpRx discount platform with more than 600 generic drugs.
usatoday.comU.S. Supreme Court declined to take up lawsuits filed by several pharmaceutical companies against the Medicare drug price negotiation program. The court did not provide a reason for its decision. The companies had already lost their appeals in lower courts.
The Maryland Prescription Drug Affordability Board agreed to set an upper payment limit for Ozempic.
The White House announced an expansion of its TrumpRx prescription drug discount platform, adding more than 600 generic drugs. The expansion includes partnerships with Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx.
Key Facts
Potential Impact
- 01
Medicare drug price negotiation program continues without further Supreme Court review.
- 02
Consumers gain access to additional generic drugs through TrumpRx platform.
- 03
Maryland residents may see capped payments for Ozempic prescriptions.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…